会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 11. 发明申请
    • STANDALONE POSITIONING IN 3G UMTS SYSTEMS USING AN EMBEDDED OR EXTERNAL GPS CHIPSET
    • 使用嵌入式或外部GPS功能的3G UMTS系统中的STANDALONE定位
    • WO2008057719A3
    • 2008-07-31
    • PCT/US2007081355
    • 2007-10-15
    • MOTOROLA INCXIONG MICHELLE HWU PING
    • XIONG MICHELLE HWU PING
    • G01S5/14H04W64/00
    • G01S19/48G01S19/41H04W64/00
    • A communications device (101) for a 3G network (115) includes a user equipment (UE) processor (206) able to determine a standalone location based on a Standalone Position Method type or standalone position method transmitted in a radio resource control (RRC) measurement control message. The 3G network (115) may command the UE processor (206) to use a standalone positioning method by transmitting a standalone position method type or standalone position method command to the communications device (101). The UE processor (206) determines the standalone location using an internal positioning module (212) such as an embedded GPS chipset, or an external positioning module (218), such as a Bluetooth accessory. UE-based location determination. UE-based preferred location determination. Assistance data. Assistance data request parameter informing whether the user equipment, UE, can/cannot request assistance data.
    • 用于3G网络(115)的通信设备(101)包括能够基于在无线电资源控制(RRC)中发送的独立位置方法类型或独立位置方法来确定独立位置的用户设备(UE)处理器(206) 测量控制信息。 3G网络(115)可以通过向通信设备(101)发送独立位置方法类型或独立位置方法命令来命令UE处理器(206)使用独立定位方法。 UE处理器(206)使用诸如嵌入式GPS芯片组的内部定位模块(212)或诸如蓝牙附件的外部定位模块(218)来确定独立位置。 基于UE的位置确定。 基于UE的优选位置确定。 援助数据。 协助数据请求参数通知用户设备UE是否能够请求协助数据。
    • 15. 发明申请
    • UNDERFILL MANAGEMENT SYSTEM FOR A BIOSENSOR
    • 生物传感器的管理系统
    • WO2011156325A3
    • 2012-03-01
    • PCT/US2011039382
    • 2011-06-07
    • BAYER HEALTHCARE LLCWU PINGMAURER ERIC
    • WU PINGMAURER ERIC
    • G01N33/487
    • G01N27/4163G01N27/327G01N27/3274G01N33/48771
    • A biosensor system including the underfill management system determines the analyte concentration in a sample from the at least one analytic output signal value. The underfill management system includes an underfill recognition system and an underfill compensation system. The underfill recognition system determines whether the test sensor initially is substantially full-filled or underfilled, indicates when the sample volume is underfilled so that additional sample may be added to the test sensor, and starts or stops the sample analysis in response to the sample volume. The underfill recognition system also may determine the initial degree of underfill. After the underfill recognition system determines the initial fill state of the test sensor, the underfill compensation system compensates the analysis based on the initial fill state of the test sensor to improve the measurement performance of the biosensor system for initially underfilled test sensors.
    • 包括底部填充管理系统的生物传感器系统从至少一个分析输出信号值确定样品中的分析物浓度。 底部填充管理系统包括底部填充识别系统和底部填充补偿系统。 底部填充识别系统确定测试传感器最初是否基本上完全填充或未充满,指示何时未充满样品体积,以便将附加样品添加到测试传感器中,并响应于样品体积开始或停止样品分析 。 底部填充识别系统还可以确定底部填充物的初始程度。 在底部填充识别系统确定测试传感器的初始填充状态之后,底部填充补偿系统将根据测试传感器的初始填充状态来补偿分析,以提高最初未充足的测试传感器的生物传感器系统的测量性能。
    • 17. 发明申请
    • TARGETS FOR DETECTION OF ISCHEMIA
    • 用于检测ISCHEMIA的目标
    • WO2006079032A3
    • 2007-01-18
    • PCT/US2006002327
    • 2006-01-23
    • ISCHEMIA TECH INCHUFF HOLLIEGEORGE SHANNONWU PING
    • HUFF HOLLIEGEORGE SHANNONWU PING
    • G06F19/00
    • G01N33/92G01N33/68G01N33/84G01N2333/76G01N2800/2871
    • The subject application comprises methods for determining the occurrence of an ischemic event in a subject by determining an ischemia score based on the amount of at least two ischemia modified albumin markers. The ischemia modified albumin markers include complexes of fatty acids bound to albumin, albumin molecules with open Cys34 sites, albumin molecules that are products of oxidation at Cys34, albumin molecules with altered conformation or altered divalent metal binding due to the conformational change or oxidation at Cys34, and albumin molecules that have been oxidized at the N-terminus. Also included in the invention are ligands to each of the foregoing ischemia modified albumin markers. Further included are methods of determining the occurrence of an ischemic event by determining the amount of fatty acid that is complexed to albumin in a patient sample. In another embodiment, an ischemic event is determined by quantitating the relative amounts of reduced and oxidized forms of albumin Cys34. In an additional embodiment, an ischemic event is determined by observing whether a shift in albumin conformation has occurred which would reflect oxidized Cys34. Further, the invention comprises a method of determining an ischemic event by determining the amount of metal ion bound to the albumin metal ion binding sites.
    • 本申请包括通过基于至少两种缺血修饰的白蛋白标记物的量确定缺血评分来确定受试者中缺血事件的发生的方法。 缺血修饰的白蛋白标志物包括与白蛋白结合的脂肪酸的复合物,具有开放Cys34位点的白蛋白分子,Cys34氧化产物的白蛋白分子,由于Cys34的构象变化或氧化而改变构象或改变的二价金属结合的白蛋白分子 和在N末端被氧化的白蛋白分子。 本发明还包括每种前述缺血修饰白蛋白标记物的配体。 还包括通过确定患者样品中与白蛋白复合的脂肪酸的量来确定缺血事件的发生的方法。 在另一个实施方案中,通过定量白蛋白Cys34的还原型和氧化形式的相对量来确定缺血事件。 在另外的实施方案中,通过观察是否已经发生将反映氧化的Cys34的白蛋白构象的位移来确定缺血事件。 此外,本发明包括通过测定与白蛋白金属离子结合位点结合的金属离子的量来测定缺血事件的方法。